Investors have been flocking to biotech stocks this year, with the IBB, the ETF that tracks biotech stocks, making noteworthy gains. So far in 2015, several industries have either underperformed or provided mixed results, leading to a rather ho-hum showpiece for U.S. blue-chip indices.Biotech stocks, on the other hand, have consistently returned positive results in the markets over the past […]
By Jason Napodano, CFAThe IBB is down 16% from its highs. That’s probably not the bottom, but it does still represent a nice buying opportunity for long-term investors.
I look for stocks with at least 12 months cash, clean capital structures, credible management, near-term catalysts, and charismatic technology.In my article I highlight some names that I either currently own or am […]
Investors have been flocking to biotech stocks this year, with the IBB, the ETF that tracks biotech stocks, making noteworthy gains. So far in 2015, several industries have either underperformed or provided mixed results, leading to a rather ho-hum showpiece for U.S. blue-chip indices.Biotech stocks, on the other hand, have consistently returned positive results in the markets over the past […]
Investors have been flocking to biotech stocks this year, with the IBB, the ETF that tracks biotech stocks, making noteworthy gains. So far in 2015, several industries have either underperformed or provided mixed results, leading to a rather ho-hum showpiece for U.S. blue-chip indices.Biotech stocks, on the other hand, have consistently returned positive results in the markets over the past […]
At Close: IBB down 2.35% to 342 at May bottom, XBI up 0.64% to 218
—-
Two Hours to Go 2:15p EDT, NASDAQ Down 1.79% at 4792, IBB at $349
Biotech Breakdown: Relief Today Or Another Head Fake?
Biotech stocks are trying to hold the May lows with the IBB at $342 but now at $349. There is bit of buying today and most biotechnology […]
By Ben LevisohnIn a note this morning, BofA Merrill Lynch’s Christina Giannini and team note that the risk for big-cap biotech stocks–think Gilead Sciences (GILD) and Biogen (BIIB)–and small-cap biotech stocks–everything else–are quite different. They explain:
Associated Press
Biotech is now more passive than actively managed: Perhaps due to the difficulty picking stocks within such an idiosyncratic sector given the complicated science […]
2015 to date, has been good for my model fund. I am up 23% vs 0% for the S&P500 and vs 20% for the IBB biotech index.
My long-term performance also remains strong – I have turned 385% over the past 10 years vs 76% for the S&P500.I anticipate the second half of 2015 will also be good for my fund. […]
I count forty seven winners, eleven losers, one break even trade for the June option cycle. While I made money, I had my first whopper loss for 2015 plus a stupid trade so grade is a C. Both the big loser and whopper loss were in AMBA. I also got whipsawed in JBLU and MRK. I made money in SKX, […]
In early April I wrote a piece arguing that biotech stocks – using the iShares Nasdaq Biotech ETF (IBB) as a proxy – looked to be under distribution. At the time the IBB traded at approximately $340. My argument rested on negative divergences in the Shares Outstanding / Price action of the IBB, Block Money Flow trends, an increase in volatility, […]
Stocks were generally lower on the day, Monday, lead by large cap names. Trading levels were light, and there were pockets of strength in growth areas. I found quite a few biotech names that looked strong, even though the IBB was negative on the day. The index, along with small cap indexes does not look as broken as the large […]
